Stäubli Robotics will present the latest generation of its Sterimove mobile robot at INTERPHEX 2026, held from April 21 to 23 in New York. The company describes this as the world’s first cleanroom-ready mobile robot designed specifically for pharmaceutical production. The enhanced Sterimove is positioned for use in sterile and aseptic manufacturing environments ranging from Grade A to Grade D. According to Stäubli, the system is built around a fully sealed architecture and cleanroom-compatible materials, enabling it to operate in controlled environments where particulate and microbial contamination must be kept to a minimum.
Sterimove was first introduced several years ago as an attempt to extend mobile robotics into high-grade pharmaceutical cleanrooms—an area traditionally dominated by fixed automation, manual carts, and human operators in protective garments. Conventional autonomous mobile robots (AMRs) are typically unsuitable for such environments due to particle generation, exposed mechanical components, and limited compatibility with decontamination procedures.
To address these constraints, Stäubli developed Sterimove with smooth, enclosed surfaces, corrosion-resistant materials, and compatibility with standard cleanroom cleaning and disinfection protocols. The platform is designed to withstand frequent wipe-downs with disinfectants and, in some configurations, hydrogen peroxide vapor (HPV) decontamination. With the updated model shown at INTERPHEX 2026, Stäubli reports further improvements in sealing, hygiene-oriented mechanical design, and system integration for sterile production workflows.
Focus on Safety and Aseptic Compliance
The latest Sterimove incorporates multiple safety and navigation features intended for operation in confined and personnel-sensitive production areas. These include collision-avoidance sensors, dual emergency stop systems, and visual status indicators for operators. From a regulatory and compliance perspective, the robot is designed to align with established hygienic design principles used in pharmaceutical and biotechnology manufacturing. This includes minimizing crevices, avoiding particle traps, and supporting validated cleaning and qualification procedures.
Stäubli positions the system as a tool for reducing manual handling of materials between isolators, filling lines, inspection systems, and packaging equipment—processes that are often associated with contamination risk and ergonomic strain. At its INTERPHEX booth, Stäubli demonstrated Sterimove as part of an integrated aseptic workflow, including automated vial handling and sealing systems. The company emphasized interoperability with isolators, robotic filling cells, and downstream packaging equipment.
Stäubli’s broader life sciences portfolio includes Stericlean+ robots for isolator and RABS environments, as well as accessPharma systems for material transfer. Sterimove is intended to complement these fixed robotic platforms by enabling automated logistics between process steps. In recent years, pharmaceutical manufacturers have increasingly explored mobile automation as a way to improve flexibility in batch-oriented production and reduce dependence on manual transport. Mobile platforms can support faster changeovers, reconfiguration of production layouts, and decentralized material handling.
Growing Interest in Mobile Pharma Robotics
The introduction of Sterimove reflects a wider trend toward automation of internal logistics in pharmaceutical facilities. While AMRs and automated guided vehicles (AGVs) are now common in general manufacturing and warehousing, their adoption in sterile environments has remained limited. Factors such as regulatory validation, cleanability, and reliability under strict environmental controls have slowed deployment. Vendors including Stäubli have sought to close this gap by developing purpose-built systems rather than adapting standard logistics robots.
Industry analysts note that demand for such solutions is being driven by the expansion of biologics, cell and gene therapies, and small-batch personalized medicines, all of which require highly controlled and flexible production environments.
